Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 13/02/2026			5-day change	1st Jan Change
58.23 ^CNY	-0.87%		+1.61%	-2.25%

02-11	Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug	MT
02-10	Kailera Therapeutics & Hengrui Pharma report positive topline data from phase 2 obesity trial of oral ribupatide	RE

Jiangsu Hengrui Pharmaceuticals Co.,Ltd(SEHK:1276) added to FTSE All-World Index

Published on 12/22/2025 at 01:37 am GMT

S&P Capital IQ

JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD

-0.87%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd(SEHK:1276) added to FTSE All-World Index (USD)

Latest news about Jiangsu Hengrui Pharmaceuticals Co.,Ltd

02-11	Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug	MT
02-10	Kailera Therapeutics & Hengrui Pharma report positive topline data from phase 2 obesity trial of oral ribupatide	RE
02-10	Kailera, Hengrui's experimental pill shows 12.1% weight loss in mid-stage trial	RE
02-10	Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide	CI
02-09	Jiangsu Hengrui Medicine Gets Breakthrough Therapy Designation for Cancer Drug	MT
02-06	Hengrui Pharmaceuticals' Gout Drug Application Accepted by Regulators	MT
01-28	China Designates Jiangsu Hengrui Medicine's Lipid Disease Tablet as Breakthrough Therapy	MT
01-27	Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials	MT
01-22	Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs	MT
01-21	Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs	MT
01-21	Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs	MT
01-20	Citigroup's long position in H shares of Jiangsu Hengrui Pharmaceuticals increases to 5.21% on Jan 14 - HKEX	RE
01-13	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
01-13	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT
01-08	Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug	MT

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Duration

Period

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276: Dynamic Chart

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

20,238

Sector

Pharmaceuticals

Calendar

03-25 - Q4 2025 Earnings Release

More about the company